




CLUNGENE® COVID-19 Antigen Rapid Test

SUMMARY



01

For Self-Testing

CLUNGENE® COVID-19 Antigen Rapid Test



| Product | Specifications | MEAS/BOX | |
|--|---|--|--|
|  <p>LUNGENE® COVID-19 Antigen Rapid Test A lateral flow immunoassay intended for the qualitative detection SARS-CoV-2 nucleocapsid antigen in nasal swab from individuals aged 7 years or older. Lateral-Flow-Immunoassay zum qualitativen Nachweis von SARS-CoV-2-Nukleokapsid-Antigenen in Nasenabstrichen von Personen ab 7 Jahren.</p> | 1 Test/Box | 165*68*20mm | |
| Extraction Reagent x1 | Test Cassette x1 | Tube x1 | Swab x1 |
|  |  |  |  |
| Packing Carton Information | MEAS/CTN | TESTS/CTN | Estimated G.W./CTN |
| | 52*35*57cm | 400tests | 14.2kg |

| Product | Specifications | MEAS/BOX | |
|--|---|--|--|
|  | 5 Tests/Box | 190*70*38mm | |
| Extraction Reagent x5 | Test Cassette x5 | Tube x5 | Swab x5 |
|  |  |  |  |
| Packing Carton Information | MEAS/CTN | TESTS/CTN | Estimated G.W./CTN |
| | 59*40*58cm | 1200tests | 20.3kg |



Tests zur Eigenanwendung durch Laien

Das BfArM hat die ersten Sonderzulassungen nach §11 Absatz 1 Medizinproduktegesetz (MPG) von Antigen-Tests zur Eigenanwendung durch Laien (Selbsttests) zum Nachweis von SARS-CoV-2 erteilt. Weitere Informationen zur rechtlichen Grundlage und den dabei geprüften Anforderungen finden Sie weiter unten auf dieser Seite unter dem Menüpunkt „Hinweise zur Sonderzulassung von Antigen-Tests durch das BfArM“.

Es handelt sich um folgende Tests, die Liste wird kontinuierlich aktualisiert:

| Aktenzeichen der Sonderzulassung des BfArM | Hersteller | Antragsteller | Testname | BfArM-AT-Nummer* |
|--|-------------------------------------|-------------------------------------|-----------------------------|------------------|
| 5640-S-168/21 | Hangzhou Clongene Biotech Co., Ltd. | Hangzhou Clongene Biotech Co., Ltd. | COVID-19 Antigen Rapid Test | |

Overview of CLUNGENE® COVID-19 Antigen Rapid Test (*For Self-Testing*)

The self-testing product is transformed from the professional-testing product (***CLUNGENE® COVID-19 Antigen Rapid Test***) manufactured by Clongene. The BfArM has granted the first special approvals according to §11 paragraph 1 of the German Medical Devices Act (MPG) of antigen tests for self-administration by laypersons (self-tests) for the detection of SARS-CoV-2. Our self-testing product can be sold and used in Germany.

Test Procedure

Take one-test kit as an example.

CLUNGENE® COVID-19 Antigen Rapid Test (For Self-Testing)

■ Test Preparation




[What is included in the test kit]



Test Cassette (1X)




Swab (1X)





Extraction Reagent (1X) Tube (1X)

Instructions for Use is
also included.


■ Sample Collection




Swab Left Nostril



Swab Right Nostril



■ Sample Preparation



■ Running the Test



BACK

02

For Professional

CLUNGENE® COVID-19 Antigen Rapid Test



National List

CLUNGENE® COVID-19 Antigen Rapid Test (For Professional)

BfArM

Listed by BfArM.

PEI

Validated by Paul-Ehrlich-Institut (PEI) in Germany.

EU

Listed in the EU common list of COVID-19 rapid antigen tests on 17 February 2021.

NAVI

Validated by Nationalen Referenzzentrum für neu auftretende Virusinfektionen (NAVI) in Switzerland, with comments as "Diese Ergebnisse liegen deutlich über den Empfehlungen der WHO für Ag-Schnelltests" by BAG.

Performance Characteristics

CLUNGENE® COVID-19 Antigen Rapid Test (For Professional)

The self-testing product is transformed from the professional-testing product (**CLUNGENE® COVID-19 Antigen Rapid Test**) manufactured by Clongene.

■ Clinical Performance

617 nasal swabs were collected from individual symptomatic patients (within 7 days of onset) and asymptomatic patients who were suspected of COVID-19. The swabs were detected by COVID-19 Antigen Rapid Test of Clongene and the RT-PCR. Summary data as below:

| COVID-19 Antigen | | RT-PCR (Ct value≤33) | | Total |
|------------------|----------|----------------------|----------|-------|
| CLUNGENE® | Positive | Positive | Negative | |
| | Positive | 132 | 3 | 135 |
| | Negative | 4 | 462 | 466 |
| Total | | 136 | 465 | 601 |

PPA (Ct≤33):97.1% (132/136), (95%CI: 92.7% ~ 98.9%)
NPA: 99.4% (462/465), (95%CI: 98.1% ~ 99.8%)

| COVID-19 Antigen | | RT-PCR (Ct value≤37) | | Total |
|------------------|----------|----------------------|----------|-------|
| CLUNGENE® | Positive | Positive | Negative | |
| | Positive | 139 | 3 | 142 |
| | Negative | 13 | 462 | 475 |
| Total | | 152 | 465 | 617 |

PPA (Ct≤37):91.4% (139/152), (95%CI: 85.9% ~ 94.9%)
NPA: 99.4% (462/465), (95%CI: 98.1% ~ 99.8%)

PPA - Positive Percent Agreement (Sensitivity)
NPA - Negative Percent Agreement(Specificity)